Once barred from giving consumers disease-related information about their DNA, 23andMe recently received approval to market such genetic tests directly to consumers—and it now has reeled in a boatload of cash to ramp up those efforts, and more. The Mountain View, CA-based genetic testing company said Tuesday it has raised a new $250 million round … Continue reading “23andMe Raises $250M For Consumer Disease-Risk Tests, Drug R&D”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
Finistere Plants Investment Seed in Ireland With $24M Agtech Fund
Ireland’s top agricultural exports are beef and dairy products. Arama Kukutai believes that in coming years, Ireland will send the United States and the rest of the world something different: innovative agricultural technologies that help make farms more productive and profitable. To that end, Kukutai’s venture capital firm, Finistere Ventures, is joining with the Ireland … Continue reading “Finistere Plants Investment Seed in Ireland With $24M Agtech Fund”
InVivo Therapeutics CSO Ulich Loses Job in Corporate Restructuring
Thomas Ulich, chief scientific officer of InVivo Therapeutics (NASDAQ: [[ticker:NVIV]]) since 2015, is out of a job. The Cambridge, MA, biotech is eliminating 13 positions, including Ulich’s, as part of a corporate restructuring, according to regulatory filings. InVivo says the restructuring will help the company focus its resources on its experimental treatment for spinal cord … Continue reading “InVivo Therapeutics CSO Ulich Loses Job in Corporate Restructuring”
BDSI’s Sirgo to Retire as CEO But Remain Vice Chairman
Mark Sirgo, president and CEO of BioDelivery Sciences International (NASDAQ: [[ticker:BDSI]]), will retire at the end of the year, the Raleigh, NC, pharmaceutical company has announced. But Sirgo will remain vice chairman of BDSI’s board of directors. The company said that the board will work with Sirgo to find his successor. Sirgo, who has been … Continue reading “BDSI’s Sirgo to Retire as CEO But Remain Vice Chairman”
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission
Eli Lilly is preparing to file again for FDA approval of rheumatoid arthritis drug baricitinib (Olumiant) by the end of January—this time with new information about the drug’s safety and efficacy. The FDA rejected the Indianapolis pharmaceutical company’s initial drug application in April. In July, Lilly (NYSE: [[ticker:LLY]]) said discussions with the regulator included the … Continue reading “Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission”
Celgene Broadens Forma Deal, Adding $195M More for Drug R&D
Celgene and Forma Therapeutics are expanding their already extensive relationship. The Summit, NJ-based drugmaker has exercised a $195 million option to widen the breadth of the 2014 deal it signed with Forma to co-develop drugs for cancer and other therapeutic areas—an agreement that gave Celgene (NASDAQ: [[ticker:CELG]]) the option to buy Forma down the road. … Continue reading “Celgene Broadens Forma Deal, Adding $195M More for Drug R&D”
Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More
ImmunoGen has yet to bring one of its own antibody cancer drugs to market, but the Waltham, MA, company has had some success with its pharma partners. On Tuesday it added Jazz Pharmaceuticals to the mix. Jazz (NASDAQ: [[ticker:JAZZ]]) is paying ImmunoGen $75 million in cash for rights to two early-stage ImmunoGen (NASDAQ: [[ticker:IMGN]]) drugs … Continue reading “Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More”
TARA Biosystems Taps MyoKardia’s Michael Graziano for CSO Post
Michael Graziano is joining TARA Biosystems to become the New York company’s chief scientific officer. TARA Biosystems is developing “heart-on-a-chip” tissue models that can be used in drug discovery and drug toxicity testing. Graziano most recently worked at South San Francisco, CA-based MyoKardia (NASDAQ: [[ticker:MYOK]]), where he was vice president of research biology. Before MyoKardia, Graziano … Continue reading “TARA Biosystems Taps MyoKardia’s Michael Graziano for CSO Post”
Iconic Therapeutics Brings Brandon Smith On Board as COO
Iconic Therapeutics has appointed Brandon Smith chief operating officer. South San Francisco, CA-based Iconic is developing therapies for retinal disease and cancer. Smith comes to Iconic from Hayward, CA-based Impax Laboratories (NASDAQ: [[ticker:IPXL]]), where he was senior vice president of corporate development and strategy. Before Impax, Smith was an executive director at Amgen (NASDAQ: [[ticker:AMGN]]), … Continue reading “Iconic Therapeutics Brings Brandon Smith On Board as COO”
SetPoint Nabs $30M For More Tests of Bioelectric Device as RA Therapy
SetPoint Medical is trying to use tiny pulses of electricity to treat inflammation in the body, and it now has an additional $30 million in funding to continue testing its approach in humans. The capital infusion announced Monday for SetPoint is a Series D round of investment. The company says it plans to use the … Continue reading “SetPoint Nabs $30M For More Tests of Bioelectric Device as RA Therapy”
RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy Companies
Dimension Therapeutics has agreed to be acquired by RegenxBio, the gene therapy developer that originally helped form the company four years ago. RegenxBio (NASDAQ: [[ticker:RGNX]]), based in Rockville, MD, will pay $3.41 per share in the all-stock deal valued at approximately $86 million. By comparison, Cambridge, MA-based Dimension (NASDAQ: [[ticker:DMTX]]) went public at $13 per … Continue reading “RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy Companies”
Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand
In these politically divided times, Americans this week found near universal agreement on one thing: A celestial event that plunges a summer day into temporary darkness is a captivating experience. The totality of the solar eclipse lasted less than 3 minutes. If you missed it, you’ll have to wait until 2024 for the next one. … Continue reading “Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand”
Atara Biosciences Appoints Kanya Rajangam Chief Medical Officer
Atara Biotherapeutics has appointed Kanya Rajangam chief medical officer. Before joining Atara (NASDAQ: [[ticker:ATRA]]), Rajangam was chief medical officer of Burlingame, CA-based Cleave Biosciences. Atara, based in South San Francisco, CA, expects to start two Phase 3 clinical trials later this year for its lead drug, ATA129, a potential treatment for certain lymphomas.
Axial Bio Names Rao Chief Medical Officer, Two Other VPs Appointed
Srinivas Rao has joined Boston-based Axial Biotherapeutics as chief medical officer. Prior to Axial, Rao was chief medical officer of Newark, CA-based Depomed (NASDAQ: [[ticker:DEPO]]). His experience includes executive roles at Kyalin Biosciences and Cypress Biosciences. Axial also appointed Ryan Barrett to vice president of corporate development, and Bridget Cole to vice president of medicinal … Continue reading “Axial Bio Names Rao Chief Medical Officer, Two Other VPs Appointed”
Brazilian Ag Bio Firm CTC Plans U.S. Expansion; RTP in Running for R&D Site
Brazilian sugarcane biotechnology company CTC is planning a U.S. expansion, and North Carolina’s Research Triangle is one of four regions on its short list for a future research and development site. Besides North Carolina, the company is also considering Florida, Louisiana, and Missouri for its new outpost. Diego Ferres, head of R&D at CTC, visited … Continue reading “Brazilian Ag Bio Firm CTC Plans U.S. Expansion; RTP in Running for R&D Site”
Memphis Meats Cooks Up $17M Funding Round for Lab-Grown “Meat”
Memphis Meats says it has developed a way to grow animal cells into products that have the look, texture, and taste of meat from farm-grown chickens. The San Francisco Bay area startup is now working to scale up its production process, and it has raised $17 million in funding toward that goal. The Series A … Continue reading “Memphis Meats Cooks Up $17M Funding Round for Lab-Grown “Meat””
Breaking Barriers & Building Bridges: Xconomy’s Diversity Award Finalists
Innovation comes from a steady flow of new ideas, and the desire to remain innovative and competitive is driving many institutional efforts to boost student and workforce diversity. The Xconomy Award finalists in the “Commitment to Diversity” category span academia and industry. A common thread among them is an effort to boost the diversity of … Continue reading “Breaking Barriers & Building Bridges: Xconomy’s Diversity Award Finalists”
Two ZS Pharma Execs Picked for Allakos Management Team
Robert Alexander has been named CEO of San Carlos, CA, drug developer Allakos. Alexander most recently served as CEO of Coppell, TX-based ZS Pharma, a subsidiary of AstraZeneca (NYSE: [[ticker:AZN]]). Before joining ZS Pharma, Alexander was a director at Alta Partners, a venture capital firm. Allakos is developing therapeutic antibody drugs to treat allergic and … Continue reading “Two ZS Pharma Execs Picked for Allakos Management Team”
Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head Test
A Novo Nordisk drug candidate for type 2 diabetes beat Eli Lilly’s dulaglutide (Trulicity) in reducing blood sugar and body weight in patients studied in a late-stage clinical trial, the Denmark-based company says. The results could bring strong competition to one of Indianapolis-based Lilly’s top-selling products if Novo Nordisk’s experimental drug is approved by the … Continue reading “Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head Test”
Allergan Veteran Kevin O’Brien Moves to Merz to Lead Neurosciences
Kevin O’Brien, a 16-year veteran of Allergan (NYSE: [[ticker:AGN]]), is joining Merz North America as vice president and U.S. head of neurosciences. O’Brien had held various roles in Allergan’s dermatology and aesthetics business. Merz North America is a subsidiary of Germany-based Merz Pharma. O’Brien will be based in Merz North America’s headquarters in Raleigh, NC.
Immune Pharma Taps Triumvira’s Tony Fiorino for CMO, COO Roles
Tony Fiorino has been named to the joint positions of chief medical officer and chief operating officer of New York-based Immune Pharmaceuticals (NASDAQ: [[ticker:IMNP]]). Fiorino will oversee research and development, clinical development, and manufacturing of Immune’s drug candidates. The company’s lead drug, bertilimumab is in mid-stage clinical testing for bullous pemphigoid, a rare autoimmune skin … Continue reading “Immune Pharma Taps Triumvira’s Tony Fiorino for CMO, COO Roles”
Pacira Pharmaceutical’s Scibetta Joins Maverick Therapeutics as CEO
James Scibetta has joined Maverick Therapeutics as CEO and member of the Brisbane, CA, biotech’s board of directors. Scibetta comes to Maverick from Parsippany, NJ-based Pacira Pharmaceuticals (NASDAQ: [[ticker:PCRX]]), where he was president. Earlier this year, Takeda Pharmaceutical signed Maverick on to a five-year, $125 million partnership pursuing new cancer immunotherapies.
Tyme Technologies Taps Eckard for Chief Scientific Affairs Post
Tyme Technologies (NASDAQ: [[ticker:TYME]]) has appointed Jonathan Eckard chief scientific affairs officer. Eckard most recently worked as chief business and strategy officer for cancer drug developer Sellas Life Sciences. New York-based Tyme’s lead drug candidate, SM-88, is in early-stage testing as a potential prostate cancer treatment.
Antibiotics Firms Cempra, Melinta Therapeutics Agree to Merger
Cempra plans to combine with Melinta Therapeutics, a merger that provides a new path forward for the Chapel Hill, NC, firm following the FDA’s surprising rejection of its lead drug late last year. Meanwhile, privately held Melinta, based in New Haven, CT, will gain a public stock listing through the deal as it prepares to … Continue reading “Antibiotics Firms Cempra, Melinta Therapeutics Agree to Merger”
UniQure Names McMillan COO, van Deventer Succeeds Retiring CSO
Scott McMillan is joining uniQure (NASDAQ: [[ticker:QURE]]) as chief operating officer. Before coming to uniQure, a gene therapy developer split between The Netherlands and Lexington, MA, McMillan was senior vice president of quality and technical operations at AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]) in Waltham, MA. McMillan will be based at uniQure’s Lexington site. In other moves, … Continue reading “UniQure Names McMillan COO, van Deventer Succeeds Retiring CSO”
Former Tobira Executive Helen Jenkins Joins Alkahest as COO
San Carlos, CA-based drug developer Alkahest has appointed Helen Jenkins as chief operating officer. Jenkins served in the same role at Tobira Therapeutics, a South San Francisco, CA, biotech that was acquired last year by Allergan (NYSE: [[ticker:AGN]]). Alkahest is developing treatments for neurodegenerative diseases and other age-related conditions.
Dermira Commits $135M for Global Rights to Roche Eczema Drug
Skin treatments developer Dermira is adding another experimental drug to its pipeline that it plans to test as a potential treatment for eczema, through a deal announced this morning with healthcare giant Roche. But in picking up the global rights to lebrikizumab, Menlo Park, CA-based Dermira (NASDAQ: [[ticker:DERM]]) is entering a suddenly crowded field of … Continue reading “Dermira Commits $135M for Global Rights to Roche Eczema Drug”
MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring
Early clinical trial data for an experimental MyoKardia drug developed to treat a potentially fatal cardiovascular disorder are showing promise, results that now have the company preparing for a larger study to support FDA approval. South San Francisco, CA-based MyoKardia (NASDAQ: [[ticker:MYOK]]) is testing the drug, mavacamten in patients who have a potentially deadly form … Continue reading “MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring”
Robot Startup Auris Reels In $280M for Less Invasive Lung Surgery
Auris Surgical Robotics has kept a tight lid on the details about its technology, its surgical targets, and its financial backers. On Friday, the stealthy startup gave a small peek at all three. San Carlos, CA-based Auris has raised $280 million in a Series D round of financing, the company revealed on its website. The … Continue reading “Robot Startup Auris Reels In $280M for Less Invasive Lung Surgery”
CRISPR Therapeutics Hires Tony Ho From AstraZeneca to Lead R&D
CRISPR Therapeutics (NASDAQ: [[ticker:CRSP]]) has hired Tony Ho to serve as the company’s executive vice president and head of research and development. Switzerland-based CRISPR Therapeutics, which maintains its R&D operations in Cambridge, MA, is developing therapies based on the CRISPR gene-editing technology. Ho comes to the company from AstraZeneca (NYSE: [[ticker:AZN]]), where he was senior … Continue reading “CRISPR Therapeutics Hires Tony Ho From AstraZeneca to Lead R&D”
Nightstar Brings Tuyen Ong On Board as Chief Development Officer
Tuyen Ong is joining Nightstar as executive vice president and chief development officer. Ong comes to Nightstar from South Plainfield, NJ-based PTC Therapeutics (NASDAQ: [[ticker:PTCT]]), where we was chief medical officer. Ong will be based in Lexington, MA, where London-based Nightstar has its U.S. headquarters. The company, which develops treatments for rare congenital retinal diseases, … Continue reading “Nightstar Brings Tuyen Ong On Board as Chief Development Officer”
Veritas Buys Curoverse to Bring A.I. Analysis of Genes to the Masses
Some answers to questions about the risk of developing a disease or a bad reaction to a drug can be found by analyzing a patient’s genes. In the not-too-distant future, such queries could be as easy as searching for and selecting a movie on Netflix, contends Rodrigo Martinez, chief marketing and design officer for Veritas … Continue reading “Veritas Buys Curoverse to Bring A.I. Analysis of Genes to the Masses”
Grail Names Chairman Bill Rastetter to Chief Executive Post
Bill Rastetter, chairman of cancer diagnostics developer Grail, has added the role of chief executive to his responsibilities at the Menlo Park, CA, company. With Rastetter’s appointment, Grail founding CEO Jeff Huber will become vice chairman of the board of directors. Grail also promoted chief business officer Ken Drazan to president. Grail spun out from … Continue reading “Grail Names Chairman Bill Rastetter to Chief Executive Post”
Mattessich Starts as New Ocular CEO, Trims Staff in Cost-Saving Move
Antony Mattessich has formally started as CEO of Ocular Therapeutix and his first move as top executive is culling the company’s headcount by 19 percent. Bedford, MA-based Ocular (NASDAQ: [[ticker:OCUL]]), whose eye drug delivery device was recently rejected by the FDA, announced last month that Mattessich would succeed Amarpreet Sawhney as CEO. Upon the change, … Continue reading “Mattessich Starts as New Ocular CEO, Trims Staff in Cost-Saving Move”
Amgen’s Roger Sidhu Joins Cell Design Labs as Chief Medical Officer
Roger Sidhu has been appointed chief medical officer of Emeryville, CA-based Cell Design Labs. Sidhu most recently worked at Amgen (NASDAQ: [[ticker:AMGN]]), where he was global product general manager. His responsibilities there encompassed Amgen’s early-stage immune-oncology compounds. Cell Design Labs, which is based on research of Wendell Lim, a professor of cellular and molecular pharmacology … Continue reading “Amgen’s Roger Sidhu Joins Cell Design Labs as Chief Medical Officer”
Flex Pharma Picks Interim Executive William McVicar for CEO
Flex Pharma’s (NASDAQ: [[ticker:FLKS]]) interim CEO, William McVicar, is now officially the company’s top executive. McVicar had been serving as interim CEO of Boston-based Flex since June. He first joined Flex in April as president of research and development. Before joining Flex, McVicar was chief scientific officer of Lexington, MA-based Inotek Pharmaceuticals (NASDAQ: [[ticker:ITEK]]). Last … Continue reading “Flex Pharma Picks Interim Executive William McVicar for CEO”
Invitae Expands Gene Test Menu With Good Start, CombiMatrix Deals
Gene tester Invitae has been clear about the company’s ambitions to make genetic information a standard part of medical practice at all stages of patient care. The San Francisco company is now aiming to offer genetic testing at the earliest stages of life by acquiring two companies that specialize in screening prospective parents and newborns. … Continue reading “Invitae Expands Gene Test Menu With Good Start, CombiMatrix Deals”
Aduro Biotech Names Andrea van Elsas Successor to CSO Thomas Dubensky
Aduro Biotech (NASDAQ: [[ticker:ADRO]]) chief scientific officer Thomas Dubensky is leaving to run his own discovery and research company, according to the cancer immunotherapy developer. Berkeley, CA-based Aduro says Dubensky’s resignation will be effective Aug. 31. He had served as Aduro’s chief scientific officer since 2011. Andrea van Elsas, currently CSO of Aduro Biotech Europe, … Continue reading “Aduro Biotech Names Andrea van Elsas Successor to CSO Thomas Dubensky”
Petra Pharma Names Brian O’Callaghan CEO and Fills CSO, CFO Posts
Brian O’Callaghan has been appointed CEO of Petra Pharma, a New York biotech developing drugs to treat cancer and metabolic diseases. O’Callaghan’s experience includes senior positions at Pfizer (NYSE: [[ticker:PFE]]), Novartis (NYSE: [[ticker:NVS]]), Merck Serono, NPS, and Covance. Petra also named David McElligott chief scientific officer, and David Renas chief financial officer. The company, which … Continue reading “Petra Pharma Names Brian O’Callaghan CEO and Fills CSO, CFO Posts”
Agtech Perspectives From Two Days With the Crop Chemicals Crowd
Spraying chemicals on crops has been a standard farming practice for decades. Pesticides and fungicides aren’t going away, but they are ceding some ground to new biological products that aim to help plants in different ways. The past year has seen market launches for microbial products developed to help plants resist stresses from pests and … Continue reading “Agtech Perspectives From Two Days With the Crop Chemicals Crowd”
Tesaro Cashes In Again on PARP Blocker With $100M Takeda Deal
Tesaro rode the clinical success of a cancer drug called niraparib (Zejula) to a three-fold increase in value over the past year. Today it’s cashed in the drug again, striking a licensing deal with Japan’s Takeda Pharmaceutical. Takeda is paying Waltham, MA-based Tesaro (NASDAQ: [[ticker:TSRO]]) $100 million up front for the rights to niraparib in … Continue reading “Tesaro Cashes In Again on PARP Blocker With $100M Takeda Deal”
Abeona Therapeutics Appoints Juan Ruiz Chief Medical Officer
Juan Ruiz has joined New York gene therapy developer Abeona Therapeutics (NASDAQ: [[ticker:ABEO]]) as chief medical officer. Ruiz’s experience includes executive positions at Lykera Biomed and Digna Biotech, both Spain-based companies. Abeona’s lead drugs are gene therapy candidates for the rare enzyme deficiency disorder Sanfilippo syndrome type A, and epidermolysis bullosa, which is a rare … Continue reading “Abeona Therapeutics Appoints Juan Ruiz Chief Medical Officer”
Eli Lilly Pays Nektar $150M Up Front For Autoimmune Drug Rights
Nektar Therapeutics has been buoyed of late by the progress of a potential pain drug, but another, much earlier program has caught the eye of Eli Lilly, which has agreed to write the San Francisco company a $150 million check to help bring the therapy through clinical testing. Depending on the progress of the drug … Continue reading “Eli Lilly Pays Nektar $150M Up Front For Autoimmune Drug Rights”
$200M Invested For a Global Network of Indoor Farms? That’s Plenty
Agtech startup Plenty has reeled in $200 million in financing as the company presses forward on its plans to build a global network of indoor vertical farms. Softbank Vision Fund of Japan led the Series B funding round for South San Francisco, CA-based Plenty. The round included investments from affiliates of Louis Bacon, the founder … Continue reading “$200M Invested For a Global Network of Indoor Farms? That’s Plenty”
NeuroVia Raises $14M to Test Drug for Rare, Fatal Metabolic Disease
Patients who have the rare genetic disorder cerebral adrenoleukodystrophy have few options to stave off the progressive decline of brain and muscle function. Within three to five years of diagnosis, the disease typically becomes fatal. A startup called NeuroVia has developed a drug that it says treats the metabolic defects that lead to the disease’s … Continue reading “NeuroVia Raises $14M to Test Drug for Rare, Fatal Metabolic Disease”
Adrian Senderowicz Joins Constellation Pharma as Chief Medical Officer
Constellation Pharmaceuticals has appointed Adrian Senderowicz senior vice president and chief medical officer. Before joining Constellation, a Cambridge, MA-based cancer immunotherapy developer, Senderowicz was chief medical officer at Waltham, MA-based Cerulean Pharma (NASDAQ: [[ticker:CERU]]). His experience includes positions at Ignyta (NASDAQ: [[ticker:RXDX]]), Sanofi Oncology (NYSE: [[ticker:SNY]]), Tokai Pharmaceuticals, and AstraZeneca (NYSE: [[ticker:AZN]]). Senderowicz also worked … Continue reading “Adrian Senderowicz Joins Constellation Pharma as Chief Medical Officer”
Radius Health Ramps Up for Market as FDA Rejects Rival Amgen Drug
Radius Health has tapped Novo Nordisk veteran Jesper Hoiland to become its new CEO as the company prepares to bring its new osteoporosis drug to the market. The appointment follows rival Amgen’s (NYSE: [[ticker:AMGN]]) Sunday night announcement that its own osteoporosis drug fell short of FDA approval. That rejection keeps the narrow field of approved … Continue reading “Radius Health Ramps Up for Market as FDA Rejects Rival Amgen Drug”
Akcea Slashes IPO Price Ahead of Filing for Rare Disease Drug
Akcea Therapeutics is joining the parade of biotechs going public, but the company had to cut its stock price and sell more shares in order to pull it off. Cambridge, MA-based Akcea had planned on raising $125 million from the initial public offering, and it hit that target. But the biotech priced its offering of … Continue reading “Akcea Slashes IPO Price Ahead of Filing for Rare Disease Drug”
Bio Roundup: PDUFA Progress, BCRA Redux, CAR-T Thumbs Up, & More
Government and industry are rife with awkward acronyms. Take PDUFA, for example. First passed in 1992, the Prescription Drug User Fee Act allows the FDA to collect fees from biopharmaceutical companies when they apply for drug approval; those funds are designated for the regulator’s drug evaluation work. Congress must reauthorize the law every five years … Continue reading “Bio Roundup: PDUFA Progress, BCRA Redux, CAR-T Thumbs Up, & More”
Zimmer Biomet’s Dvorak Out As CEO, Successor Search Underway
Zimmer Biomet is searching for a new CEO following the departure of the executive who oversaw the merger that created the medical device giant. David Dvorak stepped down from the Warsaw, IN, company’s top post effective Tuesday, a surprise move that came as the company gave an early peek at earnings data on the low … Continue reading “Zimmer Biomet’s Dvorak Out As CEO, Successor Search Underway”